−4.59USD
−615.06 MUSD
86.18 MUSD
88.44 M
About Vir Biotechnology, Inc.
Sector
Industry
CEO
Marianne de Backer
Website
Headquarters
San Francisco
Employees (FY)
587
Founded
2016
ISIN
US92764N1028
FIGI
BBG00H2QQ8T5
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of VIR is 8.10 USD — it has decreased by 1.82% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Vir Biotechnology, Inc. stocks are traded under the ticker VIR.
Vir Biotechnology, Inc. is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
VIR stock is 3.10% volatile and has beta coefficient of 1.56. Check out the list of the most volatile stocks — is Vir Biotechnology, Inc. there?
One year price forecast for Vir Biotechnology, Inc. has a max estimate of 110.00 USD and a min estimate of 10.00 USD.
VIR earnings for the last quarter are −1.22 USD whereas the estimation was −1.21 USD which accounts for −1.09% surprise. Estimated earnings for the next quarter are −1.01 USD. See more details about Vir Biotechnology, Inc. earnings.
Vir Biotechnology, Inc. revenue for the last quarter amounts to 2.64 M USD despite the estimated figure of 8.71 M USD. In the next quarter revenue is expected to reach 11.18 M USD.
Yes, you can track Vir Biotechnology, Inc. financials in yearly and quarterly reports right on TradingView.
VIR stock has fallen by 11.76% compared to the previous week, the month change is a 24.30% fall, over the last year Vir Biotechnology, Inc. has showed a 67.51% decrease.
VIR net income for the last quarter is −115.97 M USD, while the quarter before that showed −163.41 M USD of net income which accounts for 29.03% change. Track more Vir Biotechnology, Inc. financial stats to get the full picture.
Today Vir Biotechnology, Inc. has the market capitalization of 1.11 B, it has decreased by 1.35% over the last week.
No, VIR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, VIR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vir Biotechnology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 587.00 employees. See our rating of the largest employees — is Vir Biotechnology, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vir Biotechnology, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vir Biotechnology, Inc. stock shows the sell signal. See more of Vir Biotechnology, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Vir Biotechnology, Inc. future price: according to them, VIR price has a max estimate of 110.00 USD and a min estimate of 10.00 USD. Read a more detailed Vir Biotechnology, Inc. forecast: see what analysts think of Vir Biotechnology, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Vir Biotechnology, Inc. EBITDA is −614.14 M USD, and current EBITDA margin is −744.43%. See more stats in Vir Biotechnology, Inc. financial statements.